WO2024259004A1 - Systèmes et procédés de transport de cellules à température ambiante - Google Patents

Systèmes et procédés de transport de cellules à température ambiante Download PDF

Info

Publication number
WO2024259004A1
WO2024259004A1 PCT/US2024/033664 US2024033664W WO2024259004A1 WO 2024259004 A1 WO2024259004 A1 WO 2024259004A1 US 2024033664 W US2024033664 W US 2024033664W WO 2024259004 A1 WO2024259004 A1 WO 2024259004A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid solution
concentration
present
equal
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033664
Other languages
English (en)
Inventor
Ann KIESSLING
Ryan KIESSLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bedford Research Foundation
Original Assignee
Bedford Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bedford Research Foundation filed Critical Bedford Research Foundation
Publication of WO2024259004A1 publication Critical patent/WO2024259004A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Definitions

  • the present disclosure relates to the in-vitro transport of living cells at ambient temperature.
  • the transportation of cells overnight can require that cells be frozen or actively refrigerated. Freezing cells can cause mechanical stress on the cells (e.g. crystal formation, squashing, piercing, or teasing apart of cells) and cell death. After freezing, the thawing process can rupture cell membranes. Furthermore, active refrigeration can be costly during transport. Additionally, active warming to body temperature (e.g. 37 degrees Celsius) via an incubator or warming block can be costly during transport. There is a need for a cell transport solution that can maintain living cells at ambient temperatures during transportation without freezing, active refrigeration, or active warming.
  • the present disclosure provides for, and includes, a method for in-vitro transport of cells at ambient temperature.
  • a liquid solution for in-vitro transport of one or more cells comprising a methylxanthine, and one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine.
  • liquid solution for in-vitro transport of one or more cells comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate.
  • liquid solution for in-vitro transport of one or more cells comprising DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L.
  • a method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution comprising a methylxanthine, and one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • a method for inducing parthenogenesis in a gamete comprising a) placing one or more gametes into a liquid solution comprising a methylxanthine, and one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine; and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • Disclosed herein is system for cell transport comprising (i) a liquid solution comprising a methylxanthine, and one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine and (ii) a thermal insulator encapsulating the liquid solution and one or more cells.
  • a kit for cell transport comprising (i) a liquid solution comprising a methylxanthine, and one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine and (ii) a thermal insulator.
  • a method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate, and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • a method for inducing parthenogenesis in a gamete comprising a) placing one or more gametes into a liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate; and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • system for cell transport comprising (i) a liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate and (ii) a thermal insulator encapsulating the liquid solution and one or more cells.
  • kits for cell transport comprising (i) a liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate and (ii) a thermal insulator.
  • a method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution comprising DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L, and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • a method for inducing parthenogenesis in a gamete comprising a) placing one or more gametes into a liquid solution comprising DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L; and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • system for cell transport comprising (i) a liquid solution comprising DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L and (ii) a thermal insulator encapsulating the liquid solution and one or more cells.
  • kits for cell transport comprising (i) a liquid solution comprising comprising DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L and (ii) a thermal insulator.
  • FIG. 1 presents a photomicrograph of human oocytes on arrival after overnight transport at ambient temperature in HEPES -buffered liquid solution described herein.
  • FIG. 2A-B presents photomicrographs of human oocytes on arrival following overnight transport at ambient temperature in HEPES -buffered liquid solution described herein (left, A) and human oocytes following overnight transport at ambient temperature in HEPES -buffered cuture media containing cell cycle blocking agents, after subsequent overnight culture in CO2 buffered culture medium of cell cycle blocking agents (Ham F-10 Nutrient Mix, Invitrogen Catalog Number 1155043 with estrogen and progesterone at a concentration less than or equal to 1000 ng/mL) for the second night.
  • cell cycle blocking agents Ham F-10 Nutrient Mix, Invitrogen Catalog Number 1155043 with estrogen and progesterone at a concentration less than or equal to 1000 ng/mL
  • FIG. 3 A-D present photomicrographs of (A) a germinal vesical stage egg unchanged 18 hours after activation with SrCL, (B) cleavage to 2- to 6-cells by M2 stage eggs after activation with SrCh; Ml stage eggs alive, but not activated, (C) cleavage to 2- to 6-cells by M2 stage eggs after activation with calcium ionophore; Ml stage egg alive but not activated, and (D) egg arrested at 6-cell stage four days after activation with calcium ionophore.
  • FIG. 4 presents a photograph of polypropylene tubes in a polystyrene rack with a polystyrene cover placed inside a polystyrene box with batting.
  • FIG. 5 A-D present photomicrographs of a two-cell parthenote following activation including (A) Nomarski bright field photo of fixed and mounted egg, (B) ultraviolet light exposure of Hoechst-stained nuclear DNA, (C) ultraviolet light exposure of fluorescent phalloidin bound to actin filaments, and (D) composite photo of parthenote morphologically similar to two-cell embryo following fertilization of M2 egg by sperm.
  • FIG. 6 A-E present photomicrographs of a multi -cell parthenote following activation including (A) Nomarski bright field photo of fixed and mounted egg, (B) ultraviolet light exposure of Hoechst-stained nuclear DNA, (C) composite of Nomarski and Hoescht staining illustrating multi -nucleated cells, (D) ultraviolet light exposure of fluorescent-labelled phalloidin bound to actin filaments, and (E) composite photo of parthenote illustrating the discordance between karyokinesis and cytokinesis in the parthenotes activated by either strontium or ionophore.
  • FIG. 7 A-G present DIC images of fixed and cover-slipped oocytes (left) and composite renderings of fluorescent labelled phalloidin binding to actin filaments plus bright blue/white Hoechst 33258 staining of DNA (right): (A) dead, (B) Germinal Vesicle, (C) Metaphase I, (D) Metaphase II, and spontaneously activated with (E) multiple nuclei, (F) two cells, and (G) polynuclear five cells. All oocytes containing within their zone pellucida, diameter unfixed approximately 120 microns.
  • compositions and formulations A. Compositions and formulations
  • the present disclosure provides for, and includes, a liquid solution for in-vitro transport of one or more cells comprising: (i) a methylxanthine, and (ii) one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine.
  • the present disclosure provides for, and includes, a liquid solution for in-vitro transport of one or more cells comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate.
  • the present disclosure provides for, and includes, a liquid solution for in-vitro transport of one or more cells comprising: DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L.
  • methylxanthine is present in the liquid solution at a concentration from 0.1 mM to 2.0 mM. In an aspect, methylxanthine is present in the liquid solution at a concentration from 0.1 mM to 0.5 mM. In an aspect, methylxanthine is present in the liquid solution at a concentration from 0.25 mM to 0.75 mM. In an aspect, methylxanthine is present in the liquid solution at a concentration from 0.5 mM to 1.0 mM. In an aspect, methylxanthine is present in the liquid solution at a concentration from 0.75 mM to 1.25 mM.
  • methylxanthine is present in the liquid solution at a concentration from 1.0 mM to 1.5 mM. In an aspect, methylxanthine is present in the liquid solution at a concentration from 1.25 mM to 1.75 mM. In an aspect, methylxanthine is present in the liquid solution at a concentration from 1.5 mM to 2.0 mM. In an aspect, methylxanthine is present in the liquid solution at a concentration greater than or equal to 0.1 mM, 0.2mM. 0.3mM, 0.4mM. 0.5mM. 0.6mM. 0.7mM. 0.8mM. 0.9mM. l.OmM. l. lmM. 1.2mM.
  • methylxanthine is present in the liquid solution at a concentration less than or equal to 2.0 mM, 1.9mM, 1.8mM, 1.7mM, 1.6mM, 1.5mM, 1.4mM, 1.3mM, 1.2mM, l. lmM, l.OmM, 0.9mM, 0.8mM, 0.7mM, 0.6mM, 0.5mM, 0.4mM, 0.3mM, or 0.2mM. In an aspect, methylxanthine is present in the liquid solution at a concentration of 0.4mM.
  • methylxanthine comprises 1, 3, 7-trimethylpurine-2, 6-dione (caffeine) or derivative thereof.
  • caffeine or a derivative thereof is present in the liquid solution at a concentration from 0.1 mM to 2.0 mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration from 0.1 mM to 0.5 mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration from 0.25 mM to 0.75 mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration from 0.5 mM to 1.0 mM.
  • caffeine or a derivative thereof is present in the liquid solution at a concentration from 0.75 mM to 1.25 mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration from 1.0 mM to 1.5 mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration from 1.25 mM to 1.75 mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration from 1.5 mM to 2.0 mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration greater than or equal to 0.1 mM, 0.2mM. 0.3mM, 0.4mM. 0.5mM. 0.6mM. 0.7mM.
  • caffeine or a derivative thereof is present in the liquid solution at a concentration less than or equal to 2.0 mM, 1.9mM, 1.8mM, 1.7mM, 1.6mM, 1.5mM, 1.4mM, 1.3mM, 1.2mM, l. lmM, l.OmM, 0.9mM, 0.8mM, 0.7mM, 0.6mM, 0.5mM, 0.4mM, 0.3mM, or 0.2mM. In an aspect, caffeine or a derivative thereof is present in the liquid solution at a concentration of 0.4mM.
  • mammal serum protein is present in the liquid solution at a concentration less than or equal to 0.2% w/v, 0.19% w/v, 0.18% w/v, 0.17% w/v, 0.16% w/v, 0.15% w/v, 0.14% w/v, 0.13% w/v, 0.12% w/v, 0.11% w/v, 0.1% w/v, 0.09% w/v, 0.08% w/v, 0.07% w/v, 0.06% w/v, 0.05% w/v, 0.04% w/v, 0.03% w/v, 0.02% w/v, or 0.01% w/v.
  • mammal serum protein is present in the liquid solution at a concentration greater than or equal to 0.01% w/v, 0.02% w/v, 0.03% w/v, 0.04% w/v, 0.05% w/v, 0.06% w/v, 0.07% w/v, 0.08% w/v, 0.09% w/v, 0.1% w/v, 0.11% w/v, 0.12% w/v, 0.13% w/v, 0.14% w/v, 0.15% w/v, 0.16% w/v, 0.17% w/v, 0.18% w/v, 0.19% w/v, or 0.2% w/v.
  • mammal serum protein is present in the liquid solution at a concentration from 0.01% w/v to 0.2% w/v. In an aspect, mammal serum protein is present in the liquid solution at a concentration from 0.01% w/v to 0.10% w/v, from 0.05% w/v to 0.15% w/v, or from 0.10% w/v to 0.2% w/v. In an aspect, mammal serum protein comprises albumin or globulin. In an aspect, mammal serum protein is human serum protein. In an aspect, albumin comprises human serum albumin. In an aspect, globulin comprises alpha globulin or beta globulin. In an aspect, globulin comprises alpha globulin and beta globulin.
  • albumin is present in the liquid solution at a concentration less than or equal to 0.2% w/v, 0.19% w/v, 0.18% w/v, 0.17% w/v, 0.16% w/v, 0.15% w/v, 0.14% w/v, 0.13% w/v, 0.12% w/v, 0.11% w/v, 0.1% w/v, 0.09% w/v, 0.08% w/v, 0.07% w/v, 0.06% w/v, 0.05% w/v, 0.04% w/v, 0.03% w/v, 0.02% w/v, or 0.01% w/v.
  • albumin is present in the liquid solution at a concentration greater than or equal to 0.01% w/v, 0.02% w/v, 0.03% w/v, 0.04% w/v, 0.05% w/v, 0.06% w/v, 0.07% w/v, 0.08% w/v, 0.09% w/v, 0.1% w/v, 0.11% w/v, 0.12% w/v, 0.13% w/v, 0.14% w/v, 0.15% w/v, 0.16% w/v, 0.17% w/v, 0.18% w/v, 0.19% w/v, or 0.2% w/v.
  • albumin is present in the liquid solution at a concentration from 0.01% w/v to 0.2% w/v. In an aspect, albumin is present in the liquid solution at a concentration from 0.01% w/v to 0.10% w/v, from 0.05% w/v to 0.15% w/v, or from 0.10% w/v to 0.2% w/v. [0023] In an aspect, globulin is present in the liquid solution at a concentration less than or equal to 0.04% w/v, 0.03% w/v, 0.02% w/v, or 0.01% w/v.
  • globulin is present in the liquid solution at a concentration greater than or equal to 0.01% w/v, 0.02% w/v, 0.03% w/v, or 0.04% w/v. In an aspect, globulin is present in the liquid solution at a concentration from 0.01% w/v to 0.03% w/v, or from 0.02% w/v to 0.04% w/v.
  • a derivative of adenosine monophosphate is present in the liquid solution at a concentration from O.lmM to 2.0mM.
  • a derivative of adenosine monophosphate is present in the liquid solution at a concentration from O.lmM to 0.3mM, from 0.2mM to 0.4mM, from 0.3mM to 0.5mM, from 0.4mM to 0.6mM, from 0.5mM to 0.7mM, from 0.6mM to 0.8mM, from 0.7mM to 0.9mM, from 0.8mM to l.OmM, from 0.9mM to 1.
  • ImM from 1.0 mM to 1.2 mM, from 1.
  • a derivative of adenosine monophosphate is present in the liquid solution at a concentration great than or equal to O.lmM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1.0 mM, 1.1 mM, 1.2 mM, 1.3 mM, 1.4 mM, 1.5 mM, 1.6 mM, 1.7 mM, 1.8 mM, 1.9 mM, or 2.0 mM.
  • a derivative of adenosine monophosphate is present in the liquid solution at a concentration less than or equal to 2.0mM, 1.9 mM, 1.8 mM, 1.7 mM, 1.6 mM, 1.5 mM, 1.4 mM, 1.3 mM, 1.2 mM, 1.1 mM, 1.0 mM, 0.9 mM, 0.8 mM, 0.7 mM, 0.6 mM, 0.5 mM, 0.4 mM, 0.3 mM, 0.2 mM, or 0.1 mM.
  • a derivative of adenosine monophosphate comprises a cyclic adenosine monophosphate (cAMP).
  • cAMP is present in the liquid solution at a concentration from O.lmM to 2.0mM.
  • cAMP is present in the liquid solution at a concentration from O.
  • lmM to 0.3mM from 0.2mM to 0.4mM, from 0.3mM to 0.5mM, from 0.4mM to 0.6mM, from 0.5mM to 0.7mM, from 0.6mM to 0.8mM, from 0.7mM to 0.9mM, from 0.8mM to l.OmM, from 0.9mM to l.lmM, from 1.0 mM to 1.2 mM, from 1.
  • cAMP is present in the liquid solution at a concentration great than or equal to O.lmM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1.0 mM, l.
  • cAMP is present in the liquid solution at a concentration less than or equal to 2.0mM, 1.9 mM, 1.8 mM, 1.7 mM, 1.6 mM, 1.5 mM, 1.4 mM, 1.3 mM, 1.2 mM, 1.1 mM, 1.0 mM, 0.9 mM, 0.8 mM, 0.7 mM, 0.6 mM, 0.5 mM, 0.4 mM, 0.3 mM, 0.2 mM, or 0.1 mM.
  • cAMP comprises dibutyricyclicAMP.
  • dibutyricyclicAMP is present in the liquid solution at a concentration from O.lmM to 2.0mM. In an aspect, dibutyricyclicAMP is present in the liquid solution at a concentration from 0.
  • dibutyricyclicAMP is present in the liquid solution at a concentration great than or equal to O.lmM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1.0 mM, l.l mM, 1.2 mM, 1.3 mM, 1.4 mM, 1.5 mM, 1.6 mM, 1.7 mM, 1.8 mM, 1.9 mM, or 2.0 mM.
  • dibutyricyclicAMP is present in the liquid solution at a concentration less than or equal to 2.0mM, 1.9 mM, 1.8 mM, 1.7 mM, 1.6 mM, 1.5 mM, 1.4 mM, 1.3 mM, 1.2 mM, 1.1 mM, 1.0 mM, 0.9 mM, 0.8 mM, 0.7 mM, 0.6 mM, 0.5 mM, 0.4 mM, 0.3 mM, 0.2 mM, or 0.1 mM.
  • a cytokine is present in the liquid solution at a concentration greater than or equal to 5ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 25 ng/mL, 40 ng/mL, 45 ng/mL, 50 ng/mL, 55 ng/mL, 60 ng/mL, 65 ng/mL, 70 ng/mL, 75 ng/mL, 80 ng/mL, 85 ng/mL, 90 ng/mL, 95 ng/mL, or lOOng/mL.
  • a cytokine is present in the liquid solution at a concentration less than or equal to 100 ng/mL, 95 ng/mL, 90 ng/mL, 85 ng/mL, 80 ng/mL, 75 ng/mL, 70 ng/mL, 65 ng/mL, 60 ng/mL, 55 ng/mL, 50 ng/mL, 45 ng/mL, 40 ng/mL, 35 ng/mL, 30 ng/mL, 25 ng/mL, 20 ng/mL, 15 ng/mL, 10 ng/mL, or 5 ng/mL.
  • a cytokine is present in the liquid solution at a concentration between 5 ng/mL and 100 ng/mL. In an aspect, a cytokine is present in the liquid solution at a concentration from 5 ng/mL to 15ng/mL, from 10 ng/mL to 20 ng/mL, from 15 ng/mL to 25ng/mL, from 20 ng/mL to 30 ng/mL, from 25 ng/mL to 35ng/mL, from 30 ng/mL to 40 ng/mL, from 35 ng/mL to 45 ng/mL, from 40 ng/mL to 50 ng/mL, from 45 ng/mL to 55ng/mL, from 50 ng/mL to 60 ng/mL, from 55 ng/mL to 55ng/mL, from 60 ng/mL to 70 ng/mL, from 75 ng/mL to 85 ng/mL, from 80 ng/mL to 90
  • the cytokine comprises a growth factor.
  • a growth factor is present in the liquid solution at a concentration greater than or equal to 5ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 25 ng/mL, 40 ng/mL, 45 ng/mL, 50 ng/mL, 55 ng/mL, 60 ng/mL, 65 ng/mL, 70 ng/mL, 75 ng/mL, 80 ng/mL, 85 ng/mL, 90 ng/mL, 95 ng/mL, or lOOng/mL.
  • a growth factor is present in the liquid solution at a concentration less than or equal to 100 ng/mL, 95 ng/mL, 90 ng/mL, 85 ng/mL, 80 ng/mL, 75 ng/mL, 70 ng/mL, 65 ng/mL, 60 ng/mL, 55 ng/mL, 50 ng/mL, 45 ng/mL, 40 ng/mL, 35 ng/mL, 30 ng/mL, 25 ng/mL, 20 ng/mL, 15 ng/mL, 10 ng/mL, or 5 ng/mL.
  • a growth factor is present in the liquid solution at a concentration between 5 ng/mL and 100 ng/mL. In an aspect, a growth factor is present in the liquid solution at a concentration from 5 ng/mL to 15ng/mL, from 10 ng/mL to 20 ng/mL, from 15 ng/mL to 25ng/mL, from 20 ng/mL to 30 ng/mL, from 25 ng/mL to 35ng/mL, from 30 ng/mL to 40 ng/mL, from 35 ng/mL to 45 ng/mL, from 40 ng/mL to 50 ng/mL, from 45 ng/mL to 55ng/mL, from 50 ng/mL to 60 ng/mL, from 55 ng/mL to 55ng/mL, from 60 ng/mL to 70 ng/mL, from 75 ng/mL to 85 ng/mL, from 80 ng/mL to 90 ng/mL
  • a growth factor comprises insulin like growth factor 1 (IGF1) or colony stimulating factor 1 (CSF1).
  • growth factor comprises insulin like growth factor 1 (IGF1) and colony stimulating factor 1 (CSF1).
  • a grow factor comprises fibroblast growth factor 2 (FGF2), fibroblast growth factor 4 (FGF4), or cortistatin (CORT).
  • IGF1 is present in the liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • IGF1 is present in the liquid solution at a concentration from 5 ng/mL to 15ng/mL, from 10 ng/mL to 20 ng/mL, from 15 ng/mL to 25ng/mL, from 20 ng/mL to 30 ng/mL, from 25 ng/mL to 35ng/mL, from 30 ng/mL to 40 ng/mL, from 35 ng/mL to 45 ng/mL, or from 40 ng/mL to 50 ng/mL.
  • IGF1 is present in the liquid solution at a concentration less than or equal to 50 ng/mL, 45 ng/mL, 40 ng/mL, 35 ng/mL, 30 ng/mL, 25 ng/mL, 20 ng/mL, 15 ng/mL, 10 ng/mL, or 5 ng/mL. In an aspect, IGF1 is present in the liquid solution at a concentration greater than or equal to 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 25 ng/mL, 40 ng/mL, 45 ng/mL, or 50 ng/mL.
  • CSF1 is present in the liquid solution at a concentration between 5 ng/mL and 50 ng/mL. In an aspect, CSF1 is present in the liquid solution at a concentration from 5 ng/mL to 15ng/mL, from 10 ng/mL to 20 ng/mL, from 15 ng/mL to 25ng/mL, from 20 ng/mL to 30 ng/mL, from 25 ng/mL to 35ng/mL, from 30 ng/mL to 40 ng/mL, from 35 ng/mL to 45 ng/mL, or from 40 ng/mL to 50 ng/mL.
  • CSF1 is present in the liquid solution at a concentration less than or equal to 50 ng/mL, 45 ng/mL, 40 ng/mL, 35 ng/mL, 30 ng/mL, 25 ng/mL, 20 ng/mL, 15 ng/mL, 10 ng/mL, or 5 ng/mL.
  • CSF1 is present in the liquid solution at a concentration greater than or equal to 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 30 ng/mL, 25 ng/mL, 40 ng/mL, 45 ng/mL, or 50 ng/mL.
  • the liquid solution comprises a hormone.
  • a hormone is present in the liquid solution at a concentration from 5 ng/mL to 4,000 ng/mL.
  • a hormone is present in the liquid solution at a concentration from 5 ng/mL to lOOOng/mL, from 500 ng/mL to 1500 ng/mL, from 1000 ng/mL to 2000 ng/mL, from 1500 ng/mL to 2500 ng/mL, from 2000 ng/mL to 3000 ng/mL, from 2500 ng/mL to 3500 ng/mL, or from 3000 ng/mL to 4000 ng/mL.
  • a hormone is present in the liquid solution at a concentration greater than or equal to 5ng/mL, 500 ng/mL, 1000 ng/mL, 1500 ng/mL, 2000 ng/mL, 2500 ng/mL, 3000 ng/mL, 3500 ng/mL, or 4000 ng/mL. In an aspect, a hormone is present in the liquid solution at a concentration less than or equal to 4000 ng/mL, 3500 ng/mL, 3000 ng/mL, 2500 ng/mL, 2000 ng/mL, 1500 ng/mL, 1000 ng/mL, 500 ng/mL, or 5 ng/mL.
  • the hormone comprises a steroid hormone.
  • a steroid hormone is present in the liquid solution at a concentration from 5 ng/mL to 4,000 ng/mL.
  • a steroid hormone is present in the liquid solution at a concentration from 5 ng/mL to lOOOng/mL, from 500 ng/mL to 1500 ng/mL, from 1000 ng/mL to 2000 ng/mL, from 1500 ng/mL to 2500 ng/mL, from 2000 ng/mL to 3000 ng/mL, from 2500 ng/mL to 3500 ng/mL, or from 3000 ng/mL to 4000 ng/mL.
  • a steroid hormone is present in the liquid solution at a concentration greater than or equal to 5ng/mL, 500 ng/mL, 1000 ng/mL, 1500 ng/mL, 2000 ng/mL, 2500 ng/mL, 3000 ng/mL, 3500 ng/mL, or 4000 ng/mL.
  • a steroid hormone is present in the liquid solution at a concentration less than or equal to 4000 ng/mL, 3500 ng/mL, 3000 ng/mL, 2500 ng/mL, 2000 ng/mL, 1500 ng/mL, 1000 ng/mL, 500 ng/mL, or 5 ng/mL.
  • the steroid hormone comprises progesterone or estradiol. In an aspect, the steroid hormone comprises progesterone and estradiol. In an aspect, the liquid solution comprises progesterone or estradiol. In an aspect, the liquid solution comprises progesterone and estradiol.
  • progesterone is present in the liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL. In an aspect, progesterone is present in the liquid solution at a concentration from 5 ng/mL to lOOOng/mL, from 500 ng/mL to 1500 ng/mL, from 1000 ng/mL to 2000 ng/mL, from 1500 ng/mL to 2500 ng/mL, from 2000 ng/mL to 3000 ng/mL, from 2500 ng/mL to 3500 ng/mL, or from 3000 ng/mL to 4000 ng/mL.
  • progesterone is present in the liquid solution at a concentration greater than or equal to 5ng/mL, 500 ng/mL, 1000 ng/mL, 1500 ng/mL, 2000 ng/mL, 2500 ng/mL, 3000 ng/mL, 3500 ng/mL, or 4000 ng/mL. In an aspect, progesterone is present in the liquid solution at a concentration less than or equal to 4000 ng/mL, 3500 ng/mL, 3000 ng/mL, 2500 ng/mL, 2000 ng/mL, 1500 ng/mL, 1000 ng/mL, 500 ng/mL, or 5 ng/mL.
  • estradiol is present in the liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL. In an aspect, estradiol is present in the liquid solution at a concentration from 5 ng/mL to lOOOng/mL, from 500 ng/mL to 1500 ng/mL, from 1000 ng/mL to 2000 ng/mL, from 1500 ng/mL to 2500 ng/mL, from 2000 ng/mL to 3000 ng/mL, from 2500 ng/mL to 3500 ng/mL, or from 3000 ng/mL to 4000 ng/mL.
  • estradiol is present in the liquid solution at a concentration greater than or equal to 5ng/mL, 500 ng/mL, 1000 ng/mL, 1500 ng/mL, 2000 ng/mL, 2500 ng/mL, 3000 ng/mL, 3500 ng/mL, or 4000 ng/mL. In an aspect, estradiol is present in the liquid solution at a concentration less than or equal to 4000 ng/mL, 3500 ng/mL, 3000 ng/mL, 2500 ng/mL, 2000 ng/mL, 1500 ng/mL, 1000 ng/mL, 500 ng/mL, or 5 ng/mL.
  • the liquid solution comprises a zwitterionic buffering agent.
  • a zwitterionic buffering agent is present in the liquid solution at a concentration less than or equal to 0.2 M, 0.1M, 0.05M, 0.025M, or 0.01M.
  • a zwitterionic buffering agent is present in the liquid solution at a concentration greater than or equal to 0.01 M, 0.025M, 0.05M, 0.1M, or 0.2M.
  • a zwitterionic buffering agent is present in the liquid solution at a concentration from 0.01 M to 0.2 M.
  • a zwitterionic buffering agent is present in the liquid solution at a concentration from 0.01 M to 0.05 M, from 0.025 M to 0.1 M, or from 0.05 M to 0.2 M.
  • the zwitterionic buffering agent comprises N-2- hydroxylethylpiperazine-N-2-ethane sulfonic acid (HEPES).
  • HEPES is present in the liquid solution at a concentration less than or equal to 0.2 M, 0.1M, 0.05M, 0.025M, or 0.01M.
  • a HEPES is present in the liquid solution at a concentration greater than or equal to 0.01 M, 0.025M, 0.05M, 0.1M, or 0.2M.
  • HEPES is present in the liquid solution at a concentration from 0.01 M to 0.2 M.
  • HEPES is present in the liquid solution at a concentration from 0.01 M to 0.05 M, from 0.025 M to 0.1 M, or from 0.05 M to 0.2 M.
  • sulfate is present in the liquid solution at a concentration greater than or equal to 0.2 pg/mL, 0.5 pg/mL, 1.0 pg/mL, 1.5 pg/mL, or 2.0 pg/mL. In an aspect, sulfate is present in the liquid solution at a concentration less than or equal to 2.0 pg/mL, 1.5 pg/mL, 1.0 pg/mL, 0.5 pg/mL, 0.2 pg/mL. In an aspect, sulfate is present in the liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • sulfate is present in the liquid solution at a concentration from 0.2 pg/mL to 1.0 pg/mL, from 0.5 pg/mL to 1.5 pg/mL, from 1.0 pg/mL to 2.0 pg/mL.
  • the sulfate comprises zinc sulfate.
  • zinc sulfate is present in the liquid solution at a concentration greater than or equal to 0.2 pg/mL, 0.5 pg/mL, 1.0 pg/mL, 1.5 pg/mL, or 2.0 pg/mL.
  • zinc sulfate is present in the liquid solution at a concentration less than or equal to 2.0 pg/mL, 1.5 pg/mL, 1.0 pg/mL, 0.5 pg/mL, 0.2 pg/mL.
  • zinc sulfate is present in the liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL. In an aspect, zinc sulfate is present in the liquid solution at a concentration from 0.2 pg/mL to 1.0 pg/mL, from 0.5 pg/mL to 1.5 pg/mL, from 1.0 pg/mL to 2.0 pg/mL. In an aspect, zinc sulfate is present in the liquid solution at a concentration of 1 pg/mL.
  • the liquid solution comprises DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, 0.00015 g/L, or 0.0002 g/L. In an aspect, the liquid solution comprises DL lipoic acid at a concentration less than or equal to 0.00025 g/L, 0.0002g/L, 0.00015 g/L, or 0.0001 g/L. In an aspect, the liquid solution comprises DL lipoic acid at a concentration from O.OOOlg/L to 0.0002g/L, or from 0.00015g/L to 0.00025g/L. In an aspect, the liquid solution comprises DL lipoic acid at 0.0002 g/L.
  • the liquid solution comprises thymidine at a concentration greater than or equal to O.OOOlg/L, 0.0002 g/L, 0.0003 g/L, 0.0004 g/L, 0.0005 g/L, 0.0006 g/L, or 0.0007 g/L.
  • the liquid solution comprises thymidine at a concentration less than or equal to 0.0008 g/L, 0.0007 g/L, 0.0006 g/L, 0.0005 g/L, 0.0004 g/L, 0.0003 g/L, 0.0002 g/L, or 0.0001 g/L.
  • the liquid solution comprises thymidine at a concentration from O.OOOlg/L to 0.0003g/L, from 0.0002 g/L to 0.0004 g/L, from 0.0003 g/L to 0.0005 g/L, from 0.0004 g/L to 0.0006 g/L, from 0.0005 g/L to 0.0007 g/L, or from 0.0006 g/L to 0.0008 g/L.
  • the liquid solution comprises thymidine at 0.0007 g/L.
  • the liquid solution comprises sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, 0.005 g/L, 0.010 g/L, 0.02 g/L, 0.03 g/L, 0.04 g/L, 0.05 g/L, 0.06 g/L, 0.07 g/L, 0.08 g/L, 0.09 g/L, 0.10 g/L, 0.11 g/L, 0.12 g/L, 0.13 g/L, 0.14 g/L, or 0.15 g/L.
  • the liquid solution comprises sodium phosphate dibasic at a concentration less than or equal to 0.16 g/L, 0.15 g/L, 0.14 g/L, 0.13 g/L, 0.12 g/L, 0.11 g/L, 0.10 g/L, 0.09 g/L, 0.08 g/L, 0.07 g/L, 0.06 g/L, 0.05 g/L, 0.04 g/L, 0.03 g/L, 0.02 g/L, 0.01 g/L, 0.005 g/L, or O.OOOlg/L.
  • the liquid solution comprises sodium phosphate dibasic at a concentration from O.OOOlg/L to 0.16 g/L.
  • the liquid solution comprises sodium phosphate dibasic at a concentration from O.OOOlg/L to 0. Ig/L, or from 0.05g/L to 0.16 g/L. In an aspect, the liquid solution comprises a sodium phosphate dibasic at a concentration of 0.1537 g/L.
  • the liquid solution comprises sodium pyruvate at a concentration greater than or equal to O.OOOlg/L, 0.005 g/L, 0.010 g/L, 0.02 g/L, 0.03 g/L, 0.04 g/L, 0.05 g/L, 0.06 g/L, 0.07 g/L, 0.08 g/L, 0.09 g/L, 0.10 g/L, 0.11 g/L, or 0.12 g/L.
  • the liquid solution comprises sodium pyruvate at a concentration less than or equal to 0.12 g/L, 0.11 g/L, 0.10 g/L, 0.09 g/L, 0.08 g/L, 0.07 g/L, 0.06 g/L, 0.05 g/L, 0.04 g/L, 0.03 g/L, 0.02 g/L, 0.01 g/L, 0.005 g/L, or O.OOOlg/L.
  • the liquid solution comprises sodium pyruvate at a concentration O.OOOlg/L to 0. Ig/L, or from 0.05g/L to 0.12 g/L.
  • the liquid solution comprises sodium pyruvate at a concentration of 0.11 g/L.
  • the liquid solution comprises an antibiotic.
  • the antibiotic can comprise streptomycin or penicillin.
  • the liquid solution comprises Calcium Lactate (CaLactate).
  • the liquid solution comprises CaLactate at a concentration greater than or equal to O. lmM, 0.2mM, or 0.3mM.
  • the liquid solution comprises CaLactate at a concentration less than or equal to 0.3mM, 0.2mM, or 0. ImM.
  • the liquid solution comprises CaLactate at a concentration from O. lmM to 0.3mM.
  • the one or more cells described herein are mammalian cells. In an aspect, the one or more cells described herein are obtained from a subject. In an aspect, the subject is a mammal. In an aspect, the subject is a human. In an aspect, the subject is female. In an aspect, the subject is a non-human mammal.
  • the subject is in the order of Rodentia, Chiroptera, Soricomorpha, Primate, Carnivora, Artiodactyla Diprotodontia, Lagomorpha, Didelphimorphia, Cetacea, Dasyuromorphia, Afrosoricida, Erinaceomorpha, Cingulata, Peramelemorphia, Scandentia, Perissodactya, Macroscelidea, Pilosa, Monotremata, or Proboscidea.
  • the subject is a dog, a cat, a horse, a goat, a cow, a mouse, a rat, or a primate.
  • one or more cells comprise oocytes. In an aspect, one or more cells consist of oocytes. In an aspect, a cell of the one or more cells is in meiosis or metaphase II. In an aspect, a cell of the one or more cells has formed pronuclei.
  • one or more cells are at a temperature greater than 5 degrees Celsius, 6 degrees Celsius, 7 degrees Celsius, 8 degrees Celsius, 9 degrees Celsius, 10 degrees Celsius, 11 degrees Celsius, 12 degrees Celsius, 13 degrees Celsius, 14 degrees Celsius, 15 degrees Celsius, 16 degrees Celsius, 17 degrees Celsius, 18 degrees Celsius, 19 degrees Celsius, 20 degrees Celsius, 21 degrees Celsius, 22 degrees Celsius, 23 degrees Celsius, 24 degrees Celsius, 25 degrees Celsius, 26 degrees Celsius, 27 degrees Celsius, 28 degrees Celsius, 29 degrees Celsius, 30 degrees Celsius, 31 degrees Celsius, 32 degrees Celsius, 33 degrees Celsius, 34 degrees Celsius, 35 degrees Celsius, 36 degrees Celsius, 37 degrees Celsius, 38 degrees Celsius, 39 degrees Celsius, 40 degrees Celsius, 41 degrees Celsius, 42 degrees Celsius, 43 degrees Celsius, or 44 degrees Celsius.
  • the one or more cells are at a temperature of 45 degrees Celsius, 44 degrees Celsius, 43 degrees Celsius, 42 degrees Celsius, 41 degrees Celsius, 40 degrees Celsius, 39 degrees Celsius, 38 degrees Celsius, 37 degrees Celsius, 36 degrees Celsius, 35 degrees Celsius, 34 degrees Celsius, 33 degrees Celsius, 32 degrees Celsius, 31 degrees Celsius, 30 degrees Celsius, 29 degrees Celsius, 28 degrees Celsius, 27 degrees Celsius, 26 degrees Celsius, 25 degrees Celsius, 24 degrees Celsius, 23 degrees Celsius, 22 degrees Celsius, 21 degrees Celsius, 20 degrees Celsius, 19 degrees Celsius, 18 degrees Celsius, 17 degrees Celsius, 16 degrees Celsius, 15 degrees Celsius, 14 degrees Celsius, 13 degrees Celsius, 12 degrees Celsius, 11 degrees Celsius, 10 degrees Celsius, 9 degrees Celsius, 8 degrees Celsius, 7 degrees Celsius, 6 degrees Celsius, 5 degrees Celsius, or 4 degrees Celsius.
  • the one or more cells are between 4 degrees Celsius and 10 degrees Celsius, between 5 degrees Celsius and 20 degrees Celsius, between 15 degrees Celsius and 25 degrees Celsius, between 20 degrees Celsius and 30 degrees Celsius, or between 25 degrees Celsius and 38 degrees Celsius.
  • the liquid solution comprises dibutryl-cAMP, caffeine, beta-estradiol, progesterone and zinc sulfate.
  • the liquid solution comprises dibutryl-cAMP, caffeine, beta-estradiol, progesterone, sodium chloride and zinc sulfate.
  • the liquid solution comprises dibutryl-cAMP, caffeine, beta-estradiol, progesterone, zinc sulfate, insulin like growth factor 1 (IGF1), and colony stimulating factor 1 (CSF1).
  • the concentration of dibutryl-cAMP is from O. lmM to 2.0mM.
  • the concentration of caffeine is from 0. ImM to 2.0mM.
  • the concentration of estradiol is from 5ng/mL to 2,000ng/mL.
  • the concentration of progesterone is from 5 ng/mL to 2,000 ng/mL.
  • the concentration of zinc sulfate is from 0.2pg/mL to 2.0 pg/mL.
  • the concentration of insulin like growth factor (IGF1) is from 5ng/mL to 50ng/mL.
  • the concentration of colony stimulating factor 1 (CSF1) is from 5ng/mL to 50ng/mL.
  • the concentration of sodium chloride is less than 7g/L. In an aspect, the concentration of sodium chloride is less than 6g/L.
  • the concentration of sodium chloride is 5.96g/L.
  • the liquid solution comprises 0.4mM dibutyryl -cAMP, 0.4mM caffeine, lOOng/mL beta-estradiol, 50ng/mL progesterone, and 1 pg/mL zinc sulfate.
  • the liquid solution comprises 0.4mM dibutyryl-cAMP, 0.4mM caffeine, lOOng/mL beta-estradiol, 50ng/mL progesterone, 5.96 g/L sodium chloride and 1 pg/mL zinc sulfate.
  • the liquid solution comprises 0.0002g/L DL lipoic acid, 0.0007g/L thymidine, 0.1537 g/L sodium phosphate dibasic, and O. l lg/L sodium pyruvate.
  • the present disclosure provides for, and includes, a method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution comprising: (i) a methylxanthine, and (ii) one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine, and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate, and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution comprising: DL lipoic acid at a concentration greater than or equal to 0.000 Ig/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L, and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution described herein and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a method for inducing parthenogenesis in a gamete comprising: a) placing one or more gametes into a liquid solution comprising: (i) a methylxanthine, and (ii) one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine; and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a method for inducing parthenogenesis in a gamete comprising: a) placing one or more gametes into a liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate; and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a method for inducing parthenogenesis in a gamete comprising: a) placing one or more gametes into a liquid solution comprising: DL lipoic acid at a concentration greater than or equal to 0.000 Ig/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L; and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a method for inducing parthenogenesis in a gamete comprising: a) placing one or more gametes into a liquid solution described herein; and b) maintaining a temperature of the liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • maintaining a temperature of the liquid solution comprises placing the liquid solution into a vial.
  • the vial can comprise glass or plastic.
  • the vial can comprise polypropylene.
  • maintain a temperature of the liquid solution comprises placing a propylene vial is placed into thermal insulation.
  • the thermal insulation comprises polystyrene foam.
  • the temperature is maintained for more than 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, four days, five days, six days, one week, two weeks, three weeks, or four weeks.
  • the temperature is maintained greater than or equal to 4 degrees Celsius, 5 degrees Celsius, 6 degrees Celsius, 7 degrees Celsius, 8 degrees Celsius, 9 degrees Celsius, 10 degrees Celsius, 11 degrees Celsius, 12 degrees Celsius, 13 degrees Celsius, 14 degrees Celsius, 15 degrees Celsius, 16 degrees Celsius, 17 degrees Celsius, 18 degrees Celsius, 19 degrees Celsius, 20 degrees Celsius, 21 degrees Celsius, 22 degrees Celsius, 23 degrees Celsius, 24 degrees Celsius, 25 degrees Celsius, 26 degrees Celsius, 27 degrees Celsius, 28 degrees Celsius, 29 degrees Celsius, 30 degrees Celsius, 31 degrees Celsius, 32 degrees Celsius, 33 degrees Celsius, 34 degrees Celsius, 35 degrees Celsius, 36 degrees Celsius, 37 degrees Celsius, or 38 degrees Celsius.
  • the temperature is maintained less than or equal to 38 degrees Celsius, 37 degrees Celsius, 36 degrees Celsius, 35 degrees Celsius, 34 degrees Celsius, 33 degrees Celsius, 32 degrees Celsius, 31 degrees Celsius, 30 degrees Celsius, 29 degrees Celsius, 28 degrees Celsius, 27 degrees Celsius, 26 degrees Celsius, 25 degrees Celsius, 24 degrees Celsius, 23 degrees Celsius, 22 degrees Celsius, 21 degrees Celsius, 20 degrees Celsius, 19 degrees Celsius, 18 degrees Celsius, 17 degrees Celsius, 16 degrees Celsius, 15 degrees Celsius, 14 degrees Celsius, 13 degrees Celsius, 12 degrees Celsius, 11 degrees Celsius, 10 degrees Celsius, 9 degrees Celsius, 8 degrees Celsius, 7 degrees Celsius, 6 degrees Celsius, 5 degrees Celsius, or 4 degrees Celsius.
  • the temperature is maintained between 4 degrees Celsius and 10 degrees Celsius, between 5 degrees Celsius and 20 degrees Celsius, between 15 degrees Celsius and 25 degrees Celsius, between 20 degrees Celsius and 30 degrees Celsius, or between 25 degrees Celsius and 38 degrees Celsius.
  • the present disclosure provides for, and includes, a system for cell transport comprising (i) said liquid comprising: (i) a methylxanthine, and (ii) one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine, and (ii) a thermal insulator encapsulating the liquid solution and one or more cells.
  • the present disclosure provides for, and includes, a system for cell transport comprising (i) said liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate, and (ii) a thermal insulator encapsulating the liquid solution and one or more cells.
  • the present disclosure provides for, and includes, a system for cell transport comprising (i) said liquid solution comprising: DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L, and (ii) a thermal insulator encapsulating the liquid solution and one or more cells.
  • the present disclosure provides for, and includes, a system for cell transport comprising (i) said liquid solution described herein and (ii) a thermal insulator encapsulating the liquid solution and one or more cells.
  • the thermal insulator comprises polypropylene and/or polystyrene. In an aspect, the thermal insulator comprises a polypropylene vial. In an aspect, the thermal insulator comprises a polypropylene vial and/or polystyrene foam. In an aspect, the thermal insulator comprises polystyrene foam. In an aspect, the thermal insulator comprises a polystyrene foam rack. In an aspect, the polystyrene foam rack has a polystyrene foam cover. In an aspect, the thermal insulator comprises a polystyrene foam box configured to encapsulate the polystyrene foam rack. In an aspect the thermal insulator comprises a polystyrene foam box configured to encapsulate the polypropylene vial. C. Kits
  • a kit can comprise one or more of the components described herein.
  • the kit can comprise the liquid solution described herein.
  • the present disclosure provides for, and includes, a kit for cell transport comprising (i) a liquid solution comprising: (i) a methylxanthine, and (ii) one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, and a cytokine, and (ii) a thermal insulator.
  • kits for cell transport comprising (i) a liquid solution comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate, and (ii) a thermal insulator.
  • the present disclosure provides for, and includes, a kit for cell transport comprising (i) a liquid solution comprising: DL lipoic acid at a concentration greater than or equal to O.OOOlg/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to O.OOOlg/L and (ii) a thermal insulator.
  • the present disclosure provides for, and includes, a kit for cell transport comprising (i) a liquid solution described herein and (ii) a thermal insulator.
  • the kit comprises a thermometer.
  • the thermometer is digital.
  • the thermometer is an alcohol thermometer, a mercury thermometer, or an infrared thermometer.
  • the kit comprises instructions.
  • the thermal insulator comprises polypropylene and/or polystyrene. In an aspect, the thermal insulator comprises a polypropylene vial. In an aspect, the thermal insulator comprises a polypropylene vial and/or polystyrene foam. In an aspect, the thermal insulator comprises polystyrene foam. In an aspect, the thermal insulator comprises a polystyrene foam rack. In an aspect, the polystyrene foam rack has a polystyrene foam cover. In an aspect, the thermal insulator comprises a polystyrene foam box configured to encapsulate the polystyrene foam rack. In an aspect the thermal insulator comprises a polystyrene foam box configured to encapsulate the polypropylene vial.
  • the term “and/or” when used in a list of two or more items, means that any one of the listed items can be employed by itself or in combination with any one or more of the listed items.
  • the expression “A and/or B” is intended to mean either or both of A and B, i.e., A alone, B alone, or A and B in combination.
  • the expression “A, B and/or C” is intended to mean A alone, B alone, C alone, A and B in combination, A and C in combination, B and C in combination, or A, B, and C in combination.
  • parthenogenesis refers to asexual reproduction in which a gamete divides without fertilization.
  • Embodiment 1 A liquid solution for in-vitro transport of one or more cells comprising: (i) a methylxanthine, and (ii) one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, a hormone, and a cytokine.
  • Embodiment 2 The liquid solution of Embodiment 1, wherein said methylxanthine is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 3 The liquid solution of Embodiment 1, wherein said methylxanthine is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 4 The liquid solution of Embodiment 1, wherein said methylxanthine is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 5 The liquid solution of Embodiment 1, wherein said methylxanthine comprises 1, 3, 7-trimethylpurine-2, 6-dione (caffeine) or derivative thereof.
  • Embodiment 6 The liquid solution of Embodiment 5, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 7 The liquid solution of Embodiment 5, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 8 The liquid solution of Embodiment 5, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 9 The liquid solution of Embodiment 5, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 10 The liquid solution of Embodiment 1, wherein said human serum protein is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 11 The liquid solution of Embodiment 1, wherein said human serum protein is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 12 The liquid solution of Embodiment 1, wherein said human serum protein is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 13 The liquid solution of Embodiment 1, wherein said human serum protein comprises albumin or globulin.
  • Embodiment 14 The liquid solution of Embodiment 13, wherein said albumin comprises human serum albumin.
  • Embodiment 15 The liquid solution of Embodiment 13, wherein said globulin comprises alpha globulin or beta globulin.
  • Embodiment 16 The liquid solution of Embodiment 13, wherein said albumin is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 17 The liquid solution of Embodiment 13, wherein said albumin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 18 The liquid solution of Embodiment 13, wherein said albumin is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 19 The liquid solution of Embodiment 13, wherein said globulin is present in said liquid solution at a concentration less than or equal to 0.04% w/v.
  • Embodiment 20 The liquid solution of Embodiment 13, wherein said globulin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 21 The liquid solution of Embodiment 13, wherein said globulin is present in said liquid solution at a concentration from 0.01% w/v to 0.04% w/v.
  • Embodiment 22 The liquid solution of Embodiment 1, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration from O.lmM to 2.0mM.
  • Embodiment 23 The liquid solution of Embodiment 1, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration great than or equal to O.lmM.
  • Embodiment 24 The liquid solution of Embodiment 1, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 25 The liquid solution of Embodiment 1, wherein said derivative of adenosine monophosphate comprises a cyclic adenosine monophosphate (cAMP).
  • cAMP cyclic adenosine monophosphate
  • Embodiment 26 The liquid solution of Embodiment 25, wherein said cAMP is present in said liquid solution at a concentration from O.lmM to 2.0mM.
  • Embodiment 27 The liquid solution of Embodiment 25, wherein said cAMP is present in said liquid solution at a concentration great than or equal to O.lmM.
  • Embodiment 28 The liquid solution of Embodiment 25, wherein said cAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 29 The liquid solution of Embodiment 25, wherein said cAMP comprises dibutyrlcyclicAMP.
  • Embodiment 30 The liquid solution of Embodiment 29, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration from 0. ImM to 2.0mM.
  • Embodiment 31 The liquid solution of Embodiment 29, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration great than or equal to O. lmM.
  • Embodiment 32 The liquid solution of Embodiment 29, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 33 The liquid solution of Embodiment 29, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 34 The liquid solution of Embodiment 1, wherein said cytokine is present in said liquid solution at a concentration greater than or equal to 5ng/mL.
  • Embodiment 35 The liquid solution of Embodiment 1, wherein said cytokine is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 36 The liquid solution of Embodiment 1, wherein said cytokine is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 37 The liquid solution of Embodiment 1, wherein said cytokine comprises a growth factor.
  • Embodiment 38 The liquid solution of Embodiment 37, wherein said growth factor is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 39 The liquid solution of Embodiment 37, wherein said growth factor is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 40 The liquid solution of Embodiment 37, wherein said growth factor is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 41 The liquid solution of Embodiment 37, wherein said growth factor comprises insulin like growth factor 1 (IGF1) or colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 42 The liquid solution of Embodiment 41, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 43 The liquid solution of Embodiment 41, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 44 The liquid solution of Embodiment 41, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 45 The liquid solution of Embodiment 41, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 46 The liquid solution of Embodiment 41, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 47 The liquid solution of Embodiment 41, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 48 The liquid solution of Embodiment 41, wherein said growth factor comprises insulin like growth factor 1 (IGF1) and colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 49 The liquid solution of Embodiment 41, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 50 The liquid solution of Embodiment 41, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 51 The liquid solution of Embodiment 41, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 52 The liquid solution of Embodiment 41, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 53 The liquid solution of Embodiment 41, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 54 The liquid solution of Embodiment 41, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 55 The liquid solution of Embodiment 1, wherein said hormone is present in said liquid solution at a concentration from 5 ng/mL to 100 ng/mL.
  • Embodiment 56 The liquid solution of Embodiment 1, wherein said hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 57 The liquid solution of Embodiment 1, wherein said hormone is present in said liquid solution at a concentration less than 100 ng/mL.
  • Embodiment 58 The liquid solution of Embodiment 1, wherein said hormone comprises a steroid hormone.
  • Embodiment 59 The liquid solution of Embodiment 58, wherein said steroid hormone is present in said liquid solution at a concentration from 5 ng/mL to 4,000 ng/mL.
  • Embodiment 60 The liquid solution of Embodiment 58, wherein said steroid hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 61 The liquid solution of Embodiment 58, wherein said steroid hormone is present in said liquid solution at a concentration less than 4,000 ng/mL.
  • Embodiment 62 The liquid solution of Embodiment 58, wherein said steroid hormone comprises progesterone or estradiol.
  • Embodiment 63 The liquid solution of Embodiment 62, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 64 The liquid solution of Embodiment 62, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 65 The liquid solution of Embodiment 62, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 66 The liquid solution of Embodiment 62, wherein said estradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 67 The liquid solution of Embodiment 62, wherein said estradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 68 The liquid solution of Embodiment 62, wherein said estradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 69 The liquid solution of Embodiment 58, wherein said steroid hormone comprises progesterone and beta-estradiol.
  • Embodiment 70 The liquid solution of Embodiment 69, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 71 The liquid solution of Embodiment 69, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 72 The liquid solution of Embodiment 69, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 73 The liquid solution of Embodiment 69, wherein said betaestradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 74 The liquid solution of Embodiment 69, wherein said betaestradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 75 The liquid solution of Embodiment 69, wherein said betaestradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 76 The liquid solution of Embodiment 69, wherein said betaestradiol is present in said liquid solution at a concentration of 100 ng/mL.
  • Embodiment 77 The liquid solution of Embodiment 69, wherein said progesterone is present in said liquid solution at a concentration of 50 ng/mL.
  • Embodiment 78 The liquid solution of Embodiment 1, further comprising a zwitterionic buffering agent.
  • Embodiment 79. The liquid solution of Embodiment 78, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 80 The liquid solution of Embodiment 78, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 81 The liquid solution of Embodiment 78, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 82 The liquid solution of Embodiment 78, wherein said zwitterionic buffering agent comprises N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid (HEPES).
  • HEPES N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid
  • Embodiment 83 The liquid solution of Embodiment 82, wherein said HEPES is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 84 The liquid solution of Embodiment 82, wherein said HEPES is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 85 The liquid solution of Embodiment 82, wherein said HEPES is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 86 The liquid solution of Embodiment 80, wherein said HEPES is present in said liquid solution at a concentration of 0.025M.
  • Embodiment 87 The liquid solution of Embodiment 1, further comprising a sulfate
  • Embodiment 88 The liquid solution of Embodiment 87, wherein said sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 89 The liquid solution of Embodiment 87, wherein said sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 90 The liquid solution of Embodiment 87, wherein said sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 91 The liquid solution of Embodiment 87, wherein said sulfate comprises zinc sulfate.
  • Embodiment 92 The liquid solution of Embodiment 91, wherein said zinc sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 93 The liquid solution of Embodiment 91, wherein said zinc sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 94 The liquid solution of Embodiment 91, wherein said zinc sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 95 The liquid solution of Embodiment 91, wherein said zinc sulfate is present in said liquid solution at a concentration of 0.1 pg/mL.
  • Embodiment 96 The liquid solution of Embodiment 1, wherein said one or more cells comprise oocytes.
  • Embodiment 97 The liquid solution of Embodiment 1, wherein said one or more cells consist of oocytes.
  • Embodiment 98 The liquid solution of Embodiment 1, wherein a cell of said one or more cells is in meiosis or metaphase II.
  • Embodiment 99 The liquid solution of Embodiment 1, wherein a cell of said one or more cells has formed pronuclei.
  • Embodiment 100 The liquid solution of Embodiment 1, wherein said one or more cells are at a temperature greater than 5 degrees Celsius.
  • Embodiment 101 A liquid solution for in-vitro transport of one or more cells comprising: (i) a sulfate at a concentration greater than or equal to 0.9 pg/mL, and (ii) one or more of the group consisting of lipoic acid, thymidine, sodium phosphate dibasic, and sodium pyruvate.
  • Embodiment 102 The liquid solution of Embodiment 101, wherein said sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 103 The liquid solution of Embodiment 101, wherein said sulfate is present in said liquid solution at a concentration between 0.9 pg/mL and 2 pg/mL.
  • Embodiment 104 The liquid solution of Embodiment 101, wherein said sulfate comprises zinc sulfate.
  • Embodiment 105 The liquid solution of Embodiment 104, wherein said zinc sulfate is present in said liquid solution at a concentration greater than or equal to 1.0 pg/mL.
  • Embodiment 106 The liquid solution of Embodiment 104, wherein said zinc sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 107 The liquid solution of Embodiment 104, wherein said zinc sulfate is present in said liquid solution at a concentration between 0.9 pg/mL and 2 pg/mL.
  • Embodiment 108 The liquid solution of Embodiment 101, wherein said lipoic acid is present in said liquid solution at a concentration greater than or equal to 0.0001 g/L.
  • Embodiment 109 The liquid solution of Embodiment 101, wherein said lipoic acid is present in said liquid solution at a concentration between 0.0001 g/L and 0.0003 g/L.
  • Embodiment 110 The liquid solution of Embodiment 101, wherein said lipoic acid is present in said liquid solution at a concentration of 0.0002 g/L.
  • Embodiment 111 The liquid solution of Embodiment 101, wherein said lipoic acid comprises DL lipoic acid thioctic.
  • Embodiment 112. The liquid solution of Embodiment 101, wherein said thymidine is present in said liquid solution at a concentration between 0.0006 g/L and 0.0008 g/L.
  • Embodiment 113 The liquid solution of Embodiment 101, wherein said thymidine is present in said liquid solution at a concentration greater than or equal to 0.0006 g/L.
  • Embodiment 114 The liquid solution of Embodiment 101, wherein said thymidine is present in said liquid solution at a concentration of 0.0007 g/L.
  • Embodiment 115 The liquid solution of Embodiment 101, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration greater than or equal to 0.1 g/L.
  • Embodiment 116 The liquid solution of Embodiment 101, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration less than or equal to 0.2 g/L.
  • Embodiment 117 The liquid solution of Embodiment 101, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration between O. lg/L and 0.2g/L.
  • Embodiment 118 The liquid solution of Embodiment 101, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration of 0.1537 g/L.
  • Embodiment 119 The liquid solution of Embodiment 101, wherein said sodium pyruvate is present in said liquid solution at a concentration between 0.05 g/L and 0.2g/L.
  • Embodiment 120 The liquid solution of Embodiment 101, wherein said sodium pyruvate is present in said liquid solution at a concentration greater than or equal to 0.05 g/L.
  • Embodiment 121 The liquid solution of Embodiment 101, wherein said sodium pyruvate is present in said liquid solution at a concentration less than or equal to 0.2 g/L.
  • Embodiment 122 The liquid solution of Embodiment 101, wherein said sodium pyruvate is present in said liquid solution at a concentration of 0.11 g/L.
  • Embodiment 123 The liquid solution of Embodiment 1, wherein said one or more cells comprise oocytes.
  • Embodiment 124 The liquid solution of Embodiment 1, wherein a cell of said one or more cells is in meiosis or metaphase II.
  • Embodiment 125 The liquid solution of Embodiment 1, wherein a cell of said one or more cells has formed pronuclei.
  • Embodiment 126 The liquid solution of Embodiment 1, wherein said one or more cells are at a temperature greater than 5 degrees Celsius.
  • Embodiment 127 A liquid solution for in-vitro transport of one or more cells comprising DL lipoic acid at a concentration greater than or equal to 0.000 Ig/L, thymidine at a concentration greater than or equal to 0.0001 g/L, sodium phosphate dibasic at a concentration greater than or equal to O.OOOlg/L, and sodium pyruvate at a concentration greater than or equal to 0.0001 g/L.
  • Embodiment 128 The liquid solution of Embodiment 128, wherein said DL lipoic acid is present in said liquid solution at a concentration between 0.0001 g/L and 0.0003 g/L.
  • Embodiment 129 The liquid solution of Embodiment 128, wherein said DL lipoic acid is present in said liquid solution at a concentration of 0.0002 g/L.
  • Embodiment 130 The liquid solution of Embodiment 128, wherein said DL lipoic acid comprises DL lipoic acid thioctic.
  • Embodiment 131 The liquid solution of Embodiment 128, wherein said thymidine is present in said liquid solution at a concentration between 0.0006 g/L and 0.0008 g/L.
  • Embodiment 132 The liquid solution of Embodiment 128, wherein said thymidine is present in said liquid solution at a concentration greater than or equal to 0.0006 g/L.
  • Embodiment 133 The liquid solution of Embodiment 128, wherein said thymidine is present in said liquid solution at a concentration of 0.0007 g/L.
  • Embodiment 134 The liquid solution of Embodiment 128, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration greater than or equal to 0.1 g/L.
  • Embodiment 135. The liquid solution of Embodiment 128, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration less than or equal to 0.2 g/L.
  • Embodiment 136 The liquid solution of Embodiment 128, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration between O. lg/L and 0.2g/L.
  • Embodiment 137 The liquid solution of Embodiment 128, wherein said sodium phosphate dibasic is present in said liquid solution at a concentration of 0.1537 g/L.
  • Embodiment 138 The liquid solution of Embodiment 128, wherein said sodium pyruvate is present in said liquid solution at a concentration between 0.05 g/L and 0.2g/L.
  • Embodiment 139 The liquid solution of Embodiment 128, wherein said sodium pyruvate is present in said liquid solution at a concentration greater than or equal to 0.05 g/L.
  • Embodiment 140 The liquid solution of Embodiment 128, wherein said sodium pyruvate is present in said liquid solution at a concentration less than or equal to 0.2 g/L.
  • Embodiment 141 The liquid solution of Embodiment 128, wherein said sodium pyruvate is present in said liquid solution at a concentration of 0.11 g/L.
  • Embodiment 142 The liquid solution of Embodiment 128, further comprising sodium chloride at a concentration less than 7 g/L.
  • Embodiment 143 The liquid solution of Embodiment 128, further comprising sodium chloride at a concentration less than 6 g/L.
  • Embodiment 144 The liquid solution of Embodiment 128, further comprising sodium chloride at a concentration of 5.96 g/L.
  • Embodiment 145 The liquid solution of Embodiment 128, wherein said one or more cells comprise mammalian cells.
  • Embodiment 146 The liquid solution of Embodiment 128, wherein said one or more cells comprise gametes.
  • Embodiment 147 The liquid solution of Embodiment 128, wherein said one or more cells comprise an oocyte.
  • Embodiment 148 The liquid solution of Embodiment 128, wherein said one or more cells are at a temperature greater than 5 degrees Celsius.
  • Embodiment 149 A method for maintaining a respiration of one or more cells comprising: a) placing one or more cells into a liquid solution comprising:
  • Embodiment 150 The method of Embodiment 149, wherein b) comprises maintaining said temperature for greater than 8 hours.
  • Embodiment 151 The method of Embodiment 149, wherein b) comprises maintaining said temperature for greater than 12 hours.
  • Embodiment 152 The method of Embodiment 149, wherein b) comprises maintaining said temperature for greater than 24 hours.
  • Embodiment 153 The method of Embodiment 149, wherein b) comprises maintaining said temperature for greater than 48 hours.
  • Embodiment 154 The method of Embodiment 149, wherein b) comprises maintaining said temperature for greater than 72 hours.
  • Embodiment 155 The method of Embodiment 149, wherein a) comprises placing said one or more cells and said liquid solution into a polypropylene vial.
  • Embodiment 156 The method of Embodiment 155, wherein b) comprises placing said polypropylene vial into thermal insulation.
  • Embodiment 157 The method of Embodiment 156, wherein said thermal insulation comprises polystyrene foam.
  • Embodiment 158 The method of Embodiment 149, further comprising maintaining said temperature of said liquid solution at less than 30 degrees Celsius.
  • Embodiment 159 The method of Embodiment 149, further comprising maintain said temperature of said liquid solution at greater than 5 degrees Celsius.
  • Embodiment 160 The method of Embodiment 149, wherein said one or more cells comprise oocytes.
  • Embodiment 161 The method of Embodiment 149, wherein said one or more cells consist of oocytes.
  • Embodiment 162 The method of Embodiment 149, wherein a cell of said one or more cells is in meiosis or metaphase II.
  • Embodiment 163 The method of Embodiment 149, wherein said methylxanthine is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 164 The method of Embodiment 149, wherein said methylxanthine is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 165 The method of Embodiment 149, wherein said methylxanthine is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 166 The method of Embodiment 149, wherein said methylxanthine comprises 1, 3, 7-trimethylpurine-2, 6-dione (caffeine) or derivative thereof.
  • Embodiment 167 The method of Embodiment 166, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 168 The method of Embodiment 166, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 169 The method of Embodiment 166, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 170 The method of Embodiment 166, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 171 The method of Embodiment 149, wherein said human serum protein comprises albumin or globulin.
  • Embodiment 172 The method of Embodiment 171, wherein said albumin comprises human serum albumin.
  • Embodiment 173 The method of Embodiment 171, wherein said globulin comprises alpha globulin or beta globulin.
  • Embodiment 174 The method of Embodiment 171, wherein said albumin is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 175. The method of Embodiment 171, wherein said albumin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 176 The method of Embodiment 171, wherein said albumin is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 177 The method of Embodiment 171, wherein said globulin is present in said liquid solution at a concentration less than or equal to 0.04% w/v.
  • Embodiment 178 The method of Embodiment 171, wherein said globulin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 179 The method of Embodiment 171, wherein said globulin is present in said liquid solution at a concentration from 0.01% w/v to 0.04% w/v.
  • Embodiment 180 The method of Embodiment 149, wherein said derivative of adenosine monophosphate comprises a cyclic adenosine monophosphate (cAMP).
  • cAMP cyclic adenosine monophosphate
  • Embodiment 181 The method of Embodiment 180, wherein said cAMP is present in said liquid solution at a concentration from 0. ImM to 2.0mM.
  • Embodiment 182 The method of Embodiment 180, wherein said cAMP comprises dibutyrlcyclicAMP.
  • Embodiment 183 The method of Embodiment 182, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration from 0. ImM to 2.0mM.
  • Embodiment 184 The method of Embodiment 182, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration great than or equal to O. lmM.
  • Embodiment 185 The method of Embodiment 182, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 186 The method of Embodiment 182, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 187 The method of Embodiment 149, wherein said cytokine is present in said liquid solution at a concentration greater than or equal to 5ng/mL.
  • Embodiment 188 The method of Embodiment 149, wherein said cytokine comprises a growth factor.
  • Embodiment 189 The method of Embodiment 188, wherein said growth factor is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 190 The method of Embodiment 188, wherein said growth factor comprises insulin like growth factor 1 (IGF1) or colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 191 The method of Embodiment 190, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 192 The method of Embodiment 190, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 193 The method of Embodiment 190, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 194 The method of Embodiment 190, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 195 The method of Embodiment 190, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 196 The method of Embodiment 190, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 197 The method of Embodiment 190, wherein said growth factor comprises insulin like growth factor 1 (IGF1) and colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 198 The method of Embodiment 149, wherein said hormone is present in said liquid solution at a concentration from 5 ng/mL to 100 ng/mL.
  • Embodiment 199 The method of Embodiment 149, wherein said hormone comprises a steroid hormone.
  • Embodiment 200 The method of Embodiment 199, wherein said steroid hormone is present in said liquid solution at a concentration from 5 ng/mL to 4,000 ng/mL.
  • Embodiment 201 The method of Embodiment 199, wherein said steroid hormone comprises progesterone or estradiol.
  • Embodiment 202 The method of Embodiment 201, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 203 The method of Embodiment 201, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 204 The method of Embodiment 201, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 205 The method of Embodiment 201, wherein said steroid hormone comprises beta-estradiol.
  • Embodiment 206 The method of Embodiment 205, wherein said beta-estradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 207 The method of Embodiment 206, wherein said beta-estradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 208 The method of Embodiment 206, wherein said beta-estradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 209 The method of Embodiment 206, wherein said beta-estradiol is present in said liquid solution at a concentration of 100 ng/mL.
  • Embodiment 210 The method of Embodiment 206, wherein said progesterone is present in said liquid solution at a concentration of 50 ng/mL.
  • Embodiment 211 The method of Embodiment 149, further comprising a zwitterionic buffering agent.
  • Embodiment 212 The method of Embodiment 211, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 213 The method of Embodiment 211, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 214 The method of Embodiment 211, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 215. The method of Embodiment 211, wherein said zwitterionic buffering agent comprises N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid (HEPES).
  • HEPES N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid
  • Embodiment 217 The method of Embodiment 215, wherein said HEPES is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 218 The method of Embodiment 215, wherein said HEPES is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 219. The method of Embodiment 215, wherein said HEPES is present in said liquid solution at a concentration of 0.025M.
  • Embodiment 220 The method of Embodiment 149, further comprising a sulfate [00290] Embodiment 221. The method of Embodiment 220, wherein said sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 222 The method of Embodiment 220, wherein said sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 223 The method of Embodiment 220, wherein said sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 224 The method of Embodiment 220, wherein said sulfate comprises zinc sulfate.
  • Embodiment 225 The method of Embodiment 224, wherein said zinc sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 226 The method of Embodiment 224, wherein said zinc sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 227 The method of Embodiment 224, wherein said zinc sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 228 The method of Embodiment 224, wherein said zinc sulfate is present in said liquid solution at a concentration of 0.1 pg/mL.
  • Embodiment 229. The method of Embodiment 149, wherein a cell of said one or more cells has formed pronuclei.
  • Embodiment 230 A method for inducing parthenogenesis in a gamete comprising: a) placing one or more gametes into a liquid solution comprising: (i) a methylxanthine, and (ii) one or more of the group consisting of a human serum protein, a derivative of adenosine monophosphate, a hormone, and a cytokine; and b) maintaining a temperature of said liquid solution between 4 degrees Celsius and 38 degrees Celsius.
  • Embodiment 231. The method of Embodiment 230, further comprising transferring said one or more gametes into a media without said methylxanthine, and said derivative of adenosine monophosphate.
  • Embodiment 232 The method of Embodiment 230, wherein b) comprises maintaining said temperature for greater than 8 hours.
  • Embodiment 233 The method of Embodiment 230, wherein b) comprises maintaining said temperature for greater than 12 hours.
  • Embodiment 234 The method of Embodiment 230, wherein b) comprises maintaining said temperature for greater than 24 hours.
  • Embodiment 235 The method of Embodiment 230, wherein b) comprises maintaining said temperature for greater than 48 hours.
  • Embodiment 236 The method of Embodiment 230, wherein b) comprises maintaining said temperature for greater than 72 hours.
  • Embodiment 237 The method of Embodiment 230, wherein a) comprises placing said one or more cells and said liquid solution into a polypropylene vial.
  • Embodiment 238 The method of Embodiment 237, wherein b) comprises placing said propylene vial into thermal insulation.
  • Embodiment 239. The method of Embodiment 238, wherein said thermal insulation comprises polystyrene foam.
  • Embodiment 240 The method of Embodiment 230, further comprising maintaining said temperature of said liquid solution at less than 30 degrees Celsius.
  • Embodiment 241 The method of Embodiment 230, further comprising maintain said temperature of said liquid solution at greater than 5 degrees Celsius.
  • Embodiment 242 The method of Embodiment 230, wherein said one or more cells comprise oocytes.
  • Embodiment 243 The method of Embodiment 230, wherein said one or more cells consist of oocytes.
  • Embodiment 244 The method of Embodiment 230, wherein a cell of said one or more cells is in meiosis or metaphase II.
  • Embodiment 245. The method of Embodiment 230, wherein said methylxanthine is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 246 The method of Embodiment 230, wherein said methylxanthine is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 247 The method of Embodiment 230, wherein said methylxanthine is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 248 The method of Embodiment 230, wherein said methylxanthine comprises 1, 3, 7-trimethylpurine-2, 6-dione (caffeine) or derivative thereof.
  • Embodiment 249. The method of Embodiment 248, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 250 The method of Embodiment 248, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 251 The method of Embodiment 248, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 252 The method of Embodiment 248, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 253 The method of Embodiment 230, wherein said human serum protein is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 254 The method of Embodiment 230, wherein said human serum protein is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 255 The method of Embodiment 230, wherein said human serum protein is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 256 The method of Embodiment 230, wherein said human serum protein comprises albumin or globulin.
  • Embodiment 257 The method of Embodiment 256, wherein said albumin comprises human serum albumin.
  • Embodiment 258 The method of Embodiment 256, wherein said globulin comprises alpha globulin or beta globulin.
  • Embodiment 259. The method of Embodiment 256, wherein said albumin is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 260 The method of Embodiment 256, wherein said albumin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 261 The method of Embodiment 256, wherein said albumin is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 262. The method of Embodiment 256, wherein said globulin is present in said liquid solution at a concentration less than or equal to 0.04% w/v.
  • Embodiment 263 The method of Embodiment 256, wherein said globulin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 264 The method of Embodiment 256, wherein said globulin is present in said liquid solution at a concentration from 0.01% w/v to 0.04% w/v.
  • Embodiment 265. The method of Embodiment 230, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration from O.lmM to 2.0mM.
  • Embodiment 266 The method of Embodiment 230, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration great than or equal to O.lmM.
  • Embodiment 267 The method of Embodiment 230, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 268 The method of Embodiment 230, wherein said derivative of adenosine monophosphate comprises a cyclic adenosine monophosphate (cAMP).
  • cAMP cyclic adenosine monophosphate
  • Embodiment 269. The method of Embodiment 268, wherein said cAMP is present in said liquid solution at a concentration from 0. ImM to 2.0mM.
  • Embodiment 270 The method of Embodiment 268, wherein said cAMP is present in said liquid solution at a concentration great than or equal to 0. ImM.
  • Embodiment 271 The method of Embodiment 268, wherein said cAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 272 The method of Embodiment 268, wherein said cAMP comprises dibutyrlcyclicAMP.
  • Embodiment 273 The method of Embodiment 272, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration from 0. ImM to 2.0mM.
  • Embodiment 274 The method of Embodiment 272, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration great than or equal to O. lmM.
  • Embodiment 275 The method of Embodiment 272, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 276 The method of Embodiment 272, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 277 The method of Embodiment 230, wherein said cytokine is present in said liquid solution at a concentration greater than or equal to 5ng/mL.
  • Embodiment 278 The method of Embodiment 230, wherein said cytokine is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 279. The method of Embodiment 230, wherein said cytokine is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 280 The method of Embodiment 230, wherein said cytokine comprises a growth factor.
  • Embodiment 281. The method of Embodiment 280, wherein said growth factor is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 282 The method of Embodiment 280, wherein said growth factor is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 283 The method of Embodiment 280, wherein said growth factor is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 284 The method of Embodiment 280, wherein said growth factor comprises insulin like growth factor 1 (IGF1) or colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 285. The method of Embodiment 284, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 286 The method of Embodiment 284, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 287 The method of Embodiment 284, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 288 The method of Embodiment 284, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 289. The method of Embodiment 284, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 290 The method of Embodiment 284, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 291 The method of Embodiment 284, wherein said growth factor comprises insulin like growth factor 1 (IGF1) and colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 292 The method of Embodiment 284, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 293. The method of Embodiment 284, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 294 The method of Embodiment 284, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 295. The method of Embodiment 284, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 296 The method of Embodiment 284, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 297 The method of Embodiment 284, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 298 The method of Embodiment 230, wherein said hormone is present in said liquid solution at a concentration from 5 ng/mL to 100 ng/mL.
  • Embodiment 299. The method of Embodiment 230, wherein said hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 300 The method of Embodiment 230, wherein said hormone is present in said liquid solution at a concentration less than 100 ng/mL.
  • Embodiment 301 The method of Embodiment 230, wherein said hormone comprises a steroid hormone.
  • Embodiment 302. The method of Embodiment 301, wherein said steroid hormone is present in said liquid solution at a concentration from 5 ng/mL to 4,000 ng/mL.
  • Embodiment 303 The method of Embodiment 301, wherein said steroid hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 304 The method of Embodiment 301, wherein said steroid hormone is present in said liquid solution at a concentration less than 4,000 ng/mL.
  • Embodiment 305 The method of Embodiment 301, wherein said steroid hormone comprises progesterone or estradiol.
  • Embodiment 306 The method of Embodiment 305, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 307. The method of Embodiment 305, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 308 The method of Embodiment 305, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 309 The method of Embodiment 305, wherein said estradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 310 The method of Embodiment 305, wherein said estradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 311 The method of Embodiment 305, wherein said estradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 312 The method of Embodiment 301, wherein said steroid hormone comprises progesterone and beta-estradiol.
  • Embodiment 313 The method of Embodiment 312, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 314 The method of Embodiment 312, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 315 The method of Embodiment 312, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 316 The method of Embodiment 312, wherein said beta-estradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 317 The method of Embodiment 312, wherein said beta-estradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 318 The method of Embodiment 312, wherein said beta-estradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 319 The method of Embodiment 312, wherein said beta-estradiol is present in said liquid solution at a concentration of 100 ng/mL.
  • Embodiment 320 The method of Embodiment 312, wherein said progesterone is present in said liquid solution at a concentration of 50 ng/mL.
  • Embodiment 32 The method of Embodiment 230, further comprising a zwitterionic buffering agent.
  • Embodiment 322 The method of Embodiment 321, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 323 The method of Embodiment 321, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 324 The method of Embodiment 321, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 325 The method of Embodiment 321, wherein said zwitterionic buffering agent comprises N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid (HEPES).
  • HEPES N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid
  • Embodiment 327 The method of Embodiment 325, wherein said HEPES is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 328 The method of Embodiment 325, wherein said HEPES is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 329 The method of Embodiment 325, wherein said HEPES is present in said liquid solution at a concentration of 0.025M.
  • Embodiment 330 The method of Embodiment 230, further comprising a sulfate
  • Embodiment 331 The method of Embodiment 330, wherein said sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 332 The method of Embodiment 330, wherein said sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 333 The method of Embodiment 330, wherein said sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 334 The method of Embodiment 330, wherein said sulfate comprises zinc sulfate.
  • Embodiment 335 The method of Embodiment 334, wherein said zinc sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 336 The method of Embodiment 334, wherein said zinc sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 337 The method of Embodiment 334, wherein said zinc sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 338 The method of Embodiment 334, wherein said zinc sulfate is present in said liquid solution at a concentration of 0.1 pg/mL.
  • Embodiment 339 A system for cell transport comprising: a) a liquid solution comprising:
  • Embodiment 340 The system of Embodiment 339, wherein said thermal insulator comprises polystyrene foam.
  • Embodiment 341. The system of Embodiment 339, wherein said thermal insulator comprises polypropylene.
  • Embodiment 342. The system of Embodiment 339, wherein said one or more cells comprise oocytes.
  • Embodiment 343 The system of Embodiment 339, wherein said methylxanthine is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 344 The system of Embodiment 339, wherein said methylxanthine is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 345 The system of Embodiment 339, wherein said methylxanthine is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 346 The system of Embodiment 339, wherein said methylxanthine comprises 1, 3, 7-trimethylpurine-2, 6-dione (caffeine) or derivative thereof.
  • Embodiment 347 The system of Embodiment 346, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 348 The system of Embodiment 346, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 349 The system of Embodiment 346, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 350 The system of Embodiment 346, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 35 The system of Embodiment 339, wherein said human serum protein is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 352 The system of Embodiment 339, wherein said human serum protein is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 353 The system of Embodiment 339, wherein said human serum protein is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 354 The system of Embodiment 339, wherein said human serum protein comprises albumin or globulin.
  • Embodiment 355. The system of Embodiment 354, wherein said albumin comprises human serum albumin.
  • Embodiment 356 The system of Embodiment 354, wherein said globulin comprises alpha globulin or beta globulin.
  • Embodiment 357 The system of Embodiment 354, wherein said albumin is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 358 The system of Embodiment 354, wherein said albumin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 359. The system of Embodiment 354, wherein said albumin is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 360 The system of Embodiment 354, wherein said globulin is present in said liquid solution at a concentration less than or equal to 0.04% w/v.
  • Embodiment 36 The system of Embodiment 354, wherein said globulin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 362 The system of Embodiment 354, wherein said globulin is present in said liquid solution at a concentration from 0.01% w/v to 0.04% w/v.
  • Embodiment 363 The system of Embodiment 339, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration from O.lmM to 2.0mM.
  • Embodiment 36 The system of Embodiment 339, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration great than or equal to O.lmM.
  • Embodiment 365 The system of Embodiment 339, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 366 The system of Embodiment 339, wherein said derivative of adenosine monophosphate comprises a cyclic adenosine monophosphate (cAMP).
  • cAMP cyclic adenosine monophosphate
  • Embodiment 367 The system of Embodiment 366, wherein said cAMP is present in said liquid solution at a concentration from 0. ImM to 2.0mM.
  • Embodiment 368 The system of Embodiment 367, wherein said cAMP is present in said liquid solution at a concentration great than or equal to 0. ImM.
  • Embodiment 369 The system of Embodiment 367, wherein said cAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 370 The system of Embodiment 367, wherein said cAMP comprises dibutyrlcyclicAMP.
  • Embodiment 371. The system of Embodiment 370, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration from 0. ImM to 2.0mM.
  • Embodiment 372 The system of Embodiment 370, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration great than or equal to O. lmM.
  • Embodiment 373 The system of Embodiment 370, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 374 The system of Embodiment 370, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 375 The system of Embodiment 339, wherein said cytokine is present in said liquid solution at a concentration greater than or equal to 5ng/mL.
  • Embodiment 376 The system of Embodiment 339, wherein said cytokine is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 377 The system of Embodiment 339, wherein said cytokine is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 378 The system of Embodiment 339, wherein said cytokine comprises a growth factor.
  • Embodiment 379 The system of Embodiment 378, wherein said growth factor is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 380 The system of Embodiment 378, wherein said growth factor is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 38 The system of Embodiment 378, wherein said growth factor is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 382 The system of Embodiment 378, wherein said growth factor comprises insulin like growth factor 1 (IGF1) or colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 383 The system of Embodiment 382, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 384 The system of Embodiment 382, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 385 The system of Embodiment 382, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 386 The system of Embodiment 382, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 387 The system of Embodiment 382, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 388 The system of Embodiment 382, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 389 The system of Embodiment 382, wherein said growth factor comprises insulin like growth factor 1 (IGF1) and colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 390 The system of Embodiment 382, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 39 The system of Embodiment 382, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 392 The system of Embodiment 382, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 393 The system of Embodiment 382, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 394 The system of Embodiment 382, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 395 The system of Embodiment 382, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 396 The system of Embodiment 339, wherein said hormone is present in said liquid solution at a concentration from 5 ng/mL to 100 ng/mL.
  • Embodiment 397 The system of Embodiment 339, wherein said hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 398 The system of Embodiment 339, wherein said hormone is present in said liquid solution at a concentration less than 100 ng/mL.
  • Embodiment 399 The system of Embodiment 339, wherein said hormone comprises a steroid hormone.
  • Embodiment 400 The system of Embodiment 399, wherein said steroid hormone is present in said liquid solution at a concentration from 5 ng/mL to 4,000 ng/mL.
  • Embodiment 401 The system of Embodiment 399, wherein said steroid hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 402. The system of Embodiment 399, wherein said steroid hormone is present in said liquid solution at a concentration less than 4,000 ng/mL.
  • Embodiment 403. The system of Embodiment 399, wherein said steroid hormone comprises progesterone or estradiol.
  • Embodiment 404 The system of Embodiment 403, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 405. The system of Embodiment 403, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 406 The system of Embodiment 403, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 407. The system of Embodiment 403, wherein said estradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 408 The system of Embodiment 403, wherein said estradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 409 The system of Embodiment 403, wherein said estradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 410 The system of Embodiment 399, wherein said steroid hormone comprises progesterone and beta-estradiol.
  • Embodiment 411 The system of Embodiment 410, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 412 The system of Embodiment 410, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 413 The system of Embodiment 410, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 414 The system of Embodiment 410, wherein said beta-estradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 415 The system of Embodiment 410, wherein said beta-estradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 416 The system of Embodiment 410, wherein said beta-estradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 417 The system of Embodiment 410, wherein said beta-estradiol is present in said liquid solution at a concentration of 100 ng/mL.
  • Embodiment 418 The system of Embodiment 410, wherein said progesterone is present in said liquid solution at a concentration of 50 ng/mL.
  • Embodiment 419 The system of Embodiment 339, further comprising a zwitterionic buffering agent.
  • Embodiment 420 The system of Embodiment 419, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 421 The system of Embodiment 419, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 422 The system of Embodiment 419, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 423 The system of Embodiment 419, wherein said zwitterionic buffering agent comprises N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid (HEPES).
  • HEPES N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid
  • Embodiment 424 The system of Embodiment 423, wherein said HEPES is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 425 The system of Embodiment 423, wherein said HEPES is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 426 The system of Embodiment 423, wherein said HEPES is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 427 The system of Embodiment 423, wherein said HEPES is present in said liquid solution at a concentration of 0.025M.
  • Embodiment 428 The system of Embodiment 339, further comprising a sulfate
  • Embodiment 429 The system of Embodiment 428, wherein said sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 430 The system of Embodiment 428, wherein said sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 431 The system of Embodiment 428, wherein said sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 432 The system of Embodiment 428, wherein said sulfate comprises zinc sulfate.
  • Embodiment 433 The system of Embodiment 432, wherein said zinc sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 434 The system of Embodiment 432, wherein said zinc sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 435 The system of Embodiment 432, wherein said zinc sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 436 The system of Embodiment 432, wherein said zinc sulfate is present in said liquid solution at a concentration of 0.1 pg/mL.
  • kits for cell transport comprising a) a liquid solution comprising:
  • Embodiment 438 The kit of Embodiment 437, wherein said thermal insulator comprises polystyrene foam.
  • Embodiment 439 The kit of Embodiment 437, wherein said thermal insulator comprises polypropylene.
  • Embodiment 440 The kit of Embodiment 437, wherein said one or more cells comprise oocytes.
  • Embodiment 44 The kit of Embodiment 437, wherein said methylxanthine is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 442 The kit of Embodiment 437, wherein said methylxanthine is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 443 The kit of Embodiment 437, wherein said methylxanthine is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 444 The kit of Embodiment 437, wherein said methylxanthine comprises 1, 3, 7-trimethylpurine-2, 6-dione (caffeine) or derivative thereof.
  • Embodiment 445 The kit of Embodiment 444, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration from 0.1 mM to 2.0 mM.
  • Embodiment 446 The kit of Embodiment 444, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration greater than or equal to 0.1 mM.
  • Embodiment 447 The kit of Embodiment 444, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration less than or equal to 2.0 mM.
  • Embodiment 448 The kit of Embodiment 444, wherein said caffeine or derivative thereof is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 449 The kit of Embodiment 437, wherein said human serum protein is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 450 The kit of Embodiment 437, wherein said human serum protein is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 451. The kit of Embodiment 437, wherein said human serum protein is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 452 The kit of Embodiment 437, wherein said human serum protein comprises albumin or globulin.
  • Embodiment 453 The kit of Embodiment 452, wherein said albumin comprises human serum albumin.
  • Embodiment 454 The kit of Embodiment 452, wherein said globulin comprises alpha globulin or beta globulin.
  • Embodiment 455. The kit of Embodiment 452, wherein said albumin is present in said liquid solution at a concentration less than or equal to 0.2% w/v.
  • Embodiment 456 The kit of Embodiment 452, wherein said albumin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 457 The kit of Embodiment 452, wherein said albumin is present in said liquid solution at a concentration from 0.01% w/v to 0.2% w/v.
  • Embodiment 458 The kit of Embodiment 452, wherein said globulin is present in said liquid solution at a concentration less than or equal to 0.04% w/v.
  • Embodiment 45 9. The kit of Embodiment 452, wherein said globulin is present in said liquid solution at a concentration greater than or equal to 0.01% w/v.
  • Embodiment 460 The kit of Embodiment 452, wherein said globulin is present in said liquid solution at a concentration from 0.01% w/v to 0.04% w/v.
  • Embodiment 46 The kit of Embodiment 437, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration from O.lmM to 2.0mM.
  • Embodiment 462 The kit of Embodiment 437, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration great than or equal to O.lmM.
  • Embodiment 463 The kit of Embodiment 437, wherein said derivative of adenosine monophosphate is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 464 The kit of Embodiment 437, wherein said derivative of adenosine monophosphate comprises a cyclic adenosine monophosphate (cAMP).
  • cAMP cyclic adenosine monophosphate
  • Embodiment 465 The kit of Embodiment 464, wherein said cAMP is present in said liquid solution at a concentration from O.lmM to 2.0mM.
  • Embodiment 466 The kit of Embodiment 464, wherein said cAMP is present in said liquid solution at a concentration great than or equal to O.lmM.
  • Embodiment 467 The kit of Embodiment 464, wherein said cAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 468 The kit of Embodiment 464, wherein said cAMP comprises dibutyrlcyclicAMP.
  • Embodiment 469 The kit of Embodiment 468, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration from O.lmM to 2.0mM.
  • Embodiment 470 The kit of Embodiment 468, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration great than or equal to O.lmM.
  • Embodiment 471 The kit of Embodiment 468, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration less than or equal to 2.0mM.
  • Embodiment 472 The kit of Embodiment 468, wherein said dibutyrlcyclicAMP is present in said liquid solution at a concentration of 0.4mM.
  • Embodiment 473 The kit of Embodiment 437, wherein said cytokine is present in said liquid solution at a concentration greater than or equal to 5ng/mL.
  • Embodiment 474 The kit of Embodiment 437, wherein said cytokine is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 475 The kit of Embodiment 437, wherein said cytokine is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 476 The kit of Embodiment 437, wherein said cytokine comprises a growth factor.
  • Embodiment 477 The kit of Embodiment 476, wherein said growth factor is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 478 The kit of Embodiment 476, wherein said growth factor is present in said liquid solution at a concentration less than or equal to 100 ng/mL.
  • Embodiment 479 The kit of Embodiment 476, wherein said growth factor is present in said liquid solution at a concentration between 5 ng/mL and 100 ng/mL.
  • Embodiment 480 The kit of Embodiment 476, wherein said growth factor comprises insulin like growth factor 1 (IGF1) or colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 48 The kit of Embodiment 480, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 482 The kit of Embodiment 480, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 483. The kit of Embodiment 480, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 484 The kit of Embodiment 480, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 485. The kit of Embodiment 480, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 486 The kit of Embodiment 480, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 487 The kit of Embodiment 480, wherein said growth factor comprises insulin like growth factor 1 (IGF1) and colony stimulating factor 1 (CSF1).
  • IGF1 insulin like growth factor 1
  • CSF1 colony stimulating factor 1
  • Embodiment 488 The kit of Embodiment 480, wherein said IGF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 489. The kit of Embodiment 480, wherein said IGF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 490 The kit of Embodiment 480, wherein said IGF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 49 The kit of Embodiment 480, wherein said CSF1 is present in said liquid solution at a concentration between 5 ng/mL and 50 ng/mL.
  • Embodiment 492 The kit of Embodiment 480, wherein said CSF1 is present in said liquid solution at a concentration less than or equal to 50 ng/mL.
  • Embodiment 493 The kit of Embodiment 480, wherein said CSF1 is present in said liquid solution at a concentration greater than or equal to 5 ng/mL.
  • Embodiment 494 The kit of Embodiment 437, wherein said hormone is present in said liquid solution at a concentration from 5 ng/mL to 100 ng/mL.
  • Embodiment 495 The kit of Embodiment 437, wherein said hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 496 The kit of Embodiment 437, wherein said hormone is present in said liquid solution at a concentration less than 100 ng/mL.
  • Embodiment 497 The kit of Embodiment 437, wherein said hormone comprises a steroid hormone.
  • Embodiment 498 The kit of Embodiment 497, wherein said steroid hormone is present in said liquid solution at a concentration from 5 ng/mL to 4,000 ng/mL.
  • Embodiment 499 The kit of Embodiment 497, wherein said steroid hormone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 500 The kit of Embodiment 497, wherein said steroid hormone is present in said liquid solution at a concentration less than 4,000 ng/mL.
  • Embodiment 501 The kit of Embodiment 497, wherein said steroid hormone comprises progesterone or estradiol.
  • Embodiment 502. The kit of Embodiment 501, wherein said progesterone is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 503. The kit of Embodiment 501, wherein said progesterone is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 504. The kit of Embodiment 501, wherein said progesterone is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 505. The kit of Embodiment 501, wherein said estradiol is present in said liquid solution at a concentration from 5 ng/mL to 2,000 ng/mL.
  • Embodiment 506 The kit of Embodiment 501, wherein said estradiol is present in said liquid solution at a concentration greater than 5 ng/mL.
  • Embodiment 507. The kit of Embodiment 501, wherein said estradiol is present in said liquid solution at a concentration less than 2,000 ng/mL.
  • Embodiment 508 The kit of Embodiment 501, wherein said steroid hormone comprises progesterone and beta-estradiol.
  • Embodiment 509 The kit of Embodiment 437, further comprising a zwitterionic buffering agent.
  • Embodiment 510 The kit of Embodiment 509, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 511 The kit of Embodiment 509, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 512 The kit of Embodiment 509, wherein said zwitterionic buffering agent is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 513 The kit of Embodiment 509, wherein said zwitterionic buffering agent comprises N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid (HEPES).
  • HEPES N-2-hydroxylethylpiperazine-N-2-ethane sulfonic acid
  • Embodiment 514 The kit of Embodiment 513, wherein said HEPES is present in said liquid solution at a concentration less than or equal to 0.2 M.
  • Embodiment 515 The kit of Embodiment 513, wherein said HEPES is present in said liquid solution at a concentration greater than or equal to 0.01 M.
  • Embodiment 516 The kit of Embodiment 513, wherein said HEPES is present in said liquid solution at a concentration from 0.01 M to 0.2 M.
  • Embodiment 517 The kit of Embodiment 513, wherein said HEPES is present in said liquid solution at a concentration of 0.025M.
  • Embodiment 518 The kit of Embodiment 437, further comprising a sulfate
  • Embodiment 519 The kit of Embodiment 518, wherein said sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 520 The kit of Embodiment 518, wherein said sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 521 The kit of Embodiment 518, wherein said sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 522 The kit of Embodiment 518, wherein said sulfate comprises zinc sulfate.
  • Embodiment 523 The kit of Embodiment 522, wherein said zinc sulfate is present in said liquid solution at a concentration greater than or equal to 0.2 pg/mL.
  • Embodiment 524 The kit of Embodiment 522, wherein said zinc sulfate is present in said liquid solution at a concentration less than or equal to 2.0 pg/mL.
  • Embodiment 525 The kit of Embodiment 522, wherein said zinc sulfate is present in said liquid solution at a concentration between 0.2 pg/mL and 2 pg/mL.
  • Embodiment 526 The kit of Embodiment 522, wherein said zinc sulfate is present in said liquid solution at a concentration of 0.1 pg/mL.
  • the Gamete-Embryo Medium comprising the components listed in Table 1 is produced using de-ionized (DI) water:
  • the ambient temperature transport liquid solution comprising the components listed in Table 2 is produced using de-ionized (DI) water:
  • DIC differential interference contrast
  • fluorescent images are taken with a Zeiss Axiovert 200 with a Plan-Neo Fluor objective (20X magnification, NA 0.5) using a OCRA-ER digital camera (Hamamatsu) controlled by Metamorph software. Eggs are scored individually.
  • Germinal vesical stage single nucleus with fibrillar chromatin emanating from a solitary nucleolus.
  • Meiosis I(M1) condense bivalent chromosones either scattered or clustered on a spindle.
  • Meiosis 2 (M2) condense chromatids either scattered or aligned on a spindle plus polar body containing chromtin.
  • Activated Egg chromatin with a single or multiple nuclei containing prominent nucleoli. Degenerate/ Atretic Egg: granular cytoplasm, misshapen cell membrane, fragmented dispered chromatin, speckled cytoplasm, loss of network of actin filaments. Actin exhibits a network of cortical filaments in live, but not in dying or dead cells.
  • oocytes are activated in the presence of 5mM strontiuim chloride for 3.5 hours, or 2mM strontium chloride for 15 hours.
  • culture medium with standard calcium chloride (1 to 2mM) oocytes are activated with ionophore A23187 for 5 minutes followed by cytochalasin B or D for 3.5 hours.
  • Some oocytes are monitored by time-lapse photography in CytoSmart inverted microscopes placed in the Napco incubator set to 6% CO2 and 37° C. Cell culture dishes are placed on the microscope stage for periodic imaging.
  • Maturation and development following stimulation are assessed at various time points by live-cell microscopy and after fixation and mounting to visualize DNA staining with Hoeschst 3258 and fluorescent-labelled phalloidin binding to actin filaments.
  • Germinal vesical stage single nucleus with fibrillar chromatin emanating from a solitary nucleolus.
  • Meiosis I(M1) condense bivalent chromosones either scattered or clustered on a spindle.
  • Meiosis 2 (M2) condense chromatids either scattered or aligned on a spindle plus polar body containing chromtin.
  • Activated Egg chromatin with a single or multiple nuclei containing prominent nucleoli. Degenerate/ Atretic Egg: granular cytoplasm, misshapen cell membrane, fragmented dispered chromatin, speckled cytoplasm, loss of network of actin filaments. Actin demarcates cell boundaries, clarifying cleavage stages and exhibits a network of cortical filaments in live, but not dying cells.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente divulgation concerne des compositions, des systèmes et des procédés pour le transport in vitro de cellules à des températures ambiantes.
PCT/US2024/033664 2023-06-13 2024-06-12 Systèmes et procédés de transport de cellules à température ambiante Pending WO2024259004A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507874P 2023-06-13 2023-06-13
US63/507,874 2023-06-13

Publications (1)

Publication Number Publication Date
WO2024259004A1 true WO2024259004A1 (fr) 2024-12-19

Family

ID=93852604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033664 Pending WO2024259004A1 (fr) 2023-06-13 2024-06-12 Systèmes et procédés de transport de cellules à température ambiante

Country Status (1)

Country Link
WO (1) WO2024259004A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022830A1 (en) * 1996-03-22 2003-01-30 Charette Marc F. Methods for enhancing functional recovery following central nervous system ischemia or trauma
US20100009335A1 (en) * 2006-02-07 2010-01-14 Victor Joseph Temperature-regulated culture plates
US20100137676A1 (en) * 2005-04-21 2010-06-03 Goldstein Glenn A N-acetylcysteine amide (nac amide) for treatment of oxidative stress associated with infertility
US20180237799A1 (en) * 2013-03-15 2018-08-23 New York Stem Cell Foundation, Inc. Somatic cell nuclear transfer methods
US20220089666A1 (en) * 2019-08-16 2022-03-24 Applied Molecular Transport Inc. Compositions, formulations and interleukin production and purification

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022830A1 (en) * 1996-03-22 2003-01-30 Charette Marc F. Methods for enhancing functional recovery following central nervous system ischemia or trauma
US20100137676A1 (en) * 2005-04-21 2010-06-03 Goldstein Glenn A N-acetylcysteine amide (nac amide) for treatment of oxidative stress associated with infertility
US20100009335A1 (en) * 2006-02-07 2010-01-14 Victor Joseph Temperature-regulated culture plates
US20180237799A1 (en) * 2013-03-15 2018-08-23 New York Stem Cell Foundation, Inc. Somatic cell nuclear transfer methods
US20220089666A1 (en) * 2019-08-16 2022-03-24 Applied Molecular Transport Inc. Compositions, formulations and interleukin production and purification

Similar Documents

Publication Publication Date Title
Wassarman et al. Oocyte development in the mouse: an ultrastructural comparison of oocytes isolated at various stages of growth and meiotic competence
Liu et al. Freeze-dried sperm fertilization leads to full-term development in rabbits
Hsu In vitro development of individually cultured whole mouse embryos from blastocyst to early somite stage
Liu et al. Maturation of mouse primordial follicles by combination of graftingand in vitro culture
Yoshida et al. Confocal and fluorescence microscopic study using lectins of the distribution of cortical granules during the maturation and fertilization of pig oocytes
Castaneda et al. Lipid content, active mitochondria and brilliant cresyl blue staining in bovine oocytes
US5496720A (en) Parthenogenic oocyte activation
Hasegawa et al. In vitro growth and maturation as well as fertilization of mouse preantral oocytes from vitrified ovaries
Wu et al. Effects of cooling germinal vesicle–stage bovine oocytes on meiotic spindle formation following in vitro maturation
Johnston et al. Culture medium and protein supplementation influence in vitro fertilization and embryo development in the domestic cat
Nomizu et al. Zinc, iron, and copper contents of Xenopus laevis oocytes and embryos
Swanson et al. Persistence of the developmental block of in vitro fertilized domestic cat embryos to temporal variations in culture conditions
Tahaei et al. Effects of retinoic acid on maturation of immature mouse oocytes in the presence and absence of a granulosa cell co-culture system
Herrick et al. Effect of macromolecule supplementation during in vitro maturation of goat oocytes on developmental potential
Sanfins et al. Pre-implantation developmental potential from in vivo and in vitro matured mouse oocytes: a cytoskeletal perspective on oocyte quality
Chen et al. Restraint stress of female mice during oocyte development facilitates oocyte postovulatory aging
Albarracín et al. Effects of roscovitine on the nuclear and cytoskeletal components of calf oocytes and their subsequent development
Pavani et al. Novel ultrastructural findings in bovine oocytes matured in vitro
Mohr et al. In vitro fertilization and embryo growth
Gruhn et al. In vitro maturation and culture of human oocytes
WO2024259004A1 (fr) Systèmes et procédés de transport de cellules à température ambiante
Kamiyama et al. Successful delivery following intracytoplasmic sperm injection with calcium ionophore A23187 oocyte activation in a partially globozoospermic patient
Santiquet et al. Transporting cumulus complexes using novel meiotic arresting conditions permits maintenance of oocyte developmental competence
Davachi et al. Effects of co-incubation with conspecific ampulla oviductal epithelial cells and media composition on cryotolerance and developmental competence of in vitro matured sheep oocytes
US6680199B1 (en) In vitro activation of mammalian oocytes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824098

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024824098

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024824098

Country of ref document: EP

Effective date: 20260113

ENP Entry into the national phase

Ref document number: 2024824098

Country of ref document: EP

Effective date: 20260113

ENP Entry into the national phase

Ref document number: 2024824098

Country of ref document: EP

Effective date: 20260113